SUDAFED PE SINUS HEADACHE OTC
Generic Name and Formulations:
Acetaminophen 325mg, phenylephrine HCl 5mg; per caplet.
McNeil Consumer Healthcare
Indications for SUDAFED PE SINUS HEADACHE:
Nasal congestion, minor aches and pains.
2 caplets every 4 hours as needed; max 12 caplets/24hrs.
Within 14 days of MAOIs. Concomitant acetaminophen products.
Cardiovascular disease. Hypertension. Liver disease. Thyroid disease. Diabetes. GI or GU obstruction.
Analgesic + sympathomimetic.
See Contraindications. Increased risk of liver damage with ≥3 alcoholic drinks/day. Hypertensive crisis with MAOIs. β-blockers may increase the pressor effects of sympathomimetics. Antihypertensives antagonized.
Nervousness, dizziness, insomnia.
Caplets—24, 48, 72
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC